Related Experiment Video

Updated: Dec 17, 2025

Monitoring Changes in Human Umbilical Vein Endothelial Cells upon Viral Infection Using Impedance-Based Real-Time Cell Analysis
07:56

Monitoring Changes in Human Umbilical Vein Endothelial Cells upon Viral Infection Using Impedance-Based Real-Time Cell Analysis

Published on: May 5, 2023

651

COVID-19-driven endothelial damage: complement, HIF-1, and ABL2 are potential pathways of damage and targets for cure

Monia Marchetti1

  • 1Hematology Department, Az Osp SS Antonio e Biagio e Cesare Arrigo, Alessandria, Italy. moniamarchettitamellini@gmail.com.

Annals of Hematology
|June 26, 2020
PubMed

Insights

This review examines how COVID-19 causes organ damage through inflammation and endothelial dysfunction. It explores therapeutic targets and existing drugs like eculizumab for potential clinical trials.

Area of Science:

  • Cardiovascular Medicine
  • Virology
  • Immunology

Background:

  • COVID-19 pandemic presents a global health crisis with significant mortality.
  • High morbidity is linked to hypoxia and inflammation, causing endothelial dysfunction and coagulation issues.
  • Endothelial derangement affects both small and large blood vessels.

Purpose of the Study:

  • To review key pathways contributing to COVID-19-induced endothelial dysfunction.
  • To identify potential therapeutic targets for mitigating COVID-19-related organ damage.
  • To evaluate existing drugs for their suitability in clinical trials.

Main Methods:

  • Literature review focusing on molecular pathways.
  • Analysis of complement system, HIF-1α, and ABL tyrosine kinases in COVID-19.
  • Assessment of marketed drugs for therapeutic potential.

Main Results:

  • Identified complement, HIF-1α, and ABL tyrosine kinases as critical pathways in endothelial injury.
  • Highlighted potential molecular targets for intervention.
  • Eculizumab and imatinib identified as promising candidates for clinical trials.

Conclusions:

  • Understanding these pathways is crucial for managing COVID-19 complications.
  • Targeting endothelial dysfunction offers a promising therapeutic strategy.
  • Repurposing existing drugs may accelerate treatment development for COVID-19 organ damage.

Keywords:
COVID-19ComplementEculizumabEndotheliumHIF-1-alphaImatinibSARS-CoVThrombosis

More Related Videos

Screening Assays to Characterize Novel Endothelial Regulators Involved in the Inflammatory Response12:50

Screening Assays to Characterize Novel Endothelial Regulators Involved in the Inflammatory Response

Published on: September 15, 2017

6.8K
In Vitro Microfluidic Disease Model to Study Whole Blood-Endothelial Interactions and Blood Clot Dynamics in Real-Time09:19

In Vitro Microfluidic Disease Model to Study Whole Blood-Endothelial Interactions and Blood Clot Dynamics in Real-Time

Published on: May 24, 2020

9.5K

Related Concept Videos

Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
270
Complement System01:27

Complement System

The complement system is a group of approximately 20 plasma proteins that strengthen the body's defenses against infections through opsonization, inflammation, and cell lysis. Opsonization involves coating pathogens with complement proteins, making them more recognizable and facilitating phagocyte engulfment. Certain complement proteins induce inflammation that attracts immune cells to the site of infection. Cell lysis involves the destruction of pathogens through the formation of a...
8.5K
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
333
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
3.2K
Extrinsic and Intrinsic Pathways of Hemostasis01:20

Extrinsic and Intrinsic Pathways of Hemostasis

Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
11.3K
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations01:19

Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations

The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...
282